Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q1 2019 10-Q quarterly report on Apr 29, 2019 for the quarter ended Mar 31, 2019.
Neurocrine Biosciences Inc Q1 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $138.4M, up $67.3M YoY from $71.1M
- INGREZZA sales $136.4M, up from $71.1M; collaboration revenue $2.0M
- Net loss $102.1M vs $41.8M; loss per share $1.12 vs $0.47
- Cash and investments $700.8M vs $866.9M; operating cash used $112.5M
- Voyager investment $54.7M and $113.1M IPR&D charge, with no updated guidance disclosed
Risk Factors
- Newly added Voyager collaboration risk: January 2019 agreement exposed Neurocrine to development delays if Voyager halts, slows, or deprioritizes programs
- Commercialization risk: INGREZZA launch depends on maintaining personnel, infrastructure, sales capabilities, and reimbursement arrangements
- Regulatory risk: January 31, 2019 HHS proposal could modify Anti-Kickback Statute safe harbors affecting manufacturer rebates to Medicare Part D plans
- Operational risk: Limited third-party suppliers create potential INGREZZA shortages if manufacturing, quality, or compliance problems occur
- Financial risk: $517.5 million of 2.25% convertible senior notes mature May 15, 2024, with possible cash conversion obligations impacting liquidity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.